Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

Investigational New Drugs

Volumn 33, Issue 3, 2015, Pages 621-631

  Hong, David S ^a   Janku, Filip ^a   Naing, Aung ^a   Falchook, Gerald S ^a   Piha Paul, Sarina ^a   Wheler, Jennifer J ^a   Fu, Siqing ^a   Tsimberidou, Apostolia M ^a   Stecher, Michael ^b   Mohanty, Prasant ^b   Simard, John ^b   Kurzrock, Razelle ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b XBiotech USA Inc   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Checkpoint inhibitor; EGFR inhibtor; Inflammation; Interleukin 1; Interleukin 1 alpha; Non small cell lung cancer; Resistance

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; AUTACOID; EPIDERMAL GROWTH FACTOR RECEPTOR; IL1A PROTEIN, HUMAN; INTERLEUKIN 1ALPHA; MONOCLONAL ANTIBODY; XILONIX;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DRUG EFFECTS; ENERGY METABOLISM; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; QUALITY OF LIFE; SCINTISCANNING; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ENERGY METABOLISM; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1ALPHA; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; RADIONUCLIDE IMAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84937760589     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0226-6     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A (2014) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. Thornton et al (2010) Platelet interleukin-1a drives cerebrovascular inflammation. Blood 115(17):3632-3639
3. Sabrkhany et al (2011) The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 1815:189-196
4. Tjomsland V et al (2011) Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 13(8):664-675
5. Tomimatsu S, Ichikura T, Mochizuki H (2001) Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma. Cancer 91(7):1272-1276
6. Singer CF et al (2003) Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 9(13):4877-4883
7. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39(6):1003-1018. doi: 10.1016/j.immuni.2013.11.010
8. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11(8):633-652
9. Salven et al (2002) Interleukin-1α promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 16:1471-1473
10. Van Lint P, Libert C (2007) Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 82(6):1375-1381
11. Rock KL et al (2010) The sterile inflammatory response. Annu Rev Immunol 28:321-342
12. Allavena P, Mantovani A (2012) Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167(2):195-205. doi: 10.1111/j.1365-2249.2011.04515.x
13. Dinarello CA (2014) Interleukin-1α neutralisation in patients with cancer. Lancet Oncol 15(6):552-553. doi: 10.1016/S1470-2045(14)70164-0
14. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026
15. Wolchok JD et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412-7420
16. Quinten C et al (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865-871
17. Hong DS et al (2014) MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 15(6):656-666
18. Yeh KY, Li YY, Hsieh LL et al (2010) Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer. Jpn J Clin Oncol 40(6):580-587. doi: 10.1093/jjco/hyq010
19. Stone RL, Nick AM, McNeish IA et al (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610-618. doi: 10.1056/NEJMoa1110352
20. Ravasco P, Monteiro-Grillo I, Camilo M (2007) Colorectal cancer: intrinsic characteristics modulate cancer energy expenditure and the risk of cachexia. Cancer Invest 25(5):308-314
21. Quinten C, Coens C, Mauer M et al (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10(9):865-871. doi: 10.1016/S1470-2045(09)70200-1
22. Herrmann F et al (2004) HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64:215-220
23. Mimura K (2004) T. et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 128:390-401
24. So T et al (2005) Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 65(13):5945-5952
25. Corthay A (2014) Does the immune system naturally protect against cancer? Front Immunol 5:197. doi: 10.3389/fimmu.2014.00197. eCollection 2014
26. Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27:5869-5885. doi: 10.1038/onc.2008.273
27. Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, Ferris RL (2014) Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol
28. Pollack BP, Sapkota B, Cartee TV (2011) Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 17:4400-4413
29. Voronov E, Carmi Y, Apte RN (2014) The role IL-1 in tumor-mediated angiogenesis. Front Physiol 5:114. doi: 10.3389/fphys.2014.00114, eCollection 2014
30. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499-4506. doi: 10.4049/jimmunol.0802740
31. Kim B et al (2013) The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol 4:391. doi: 10.3389/fimmu.2013.00391. eCollection 2013
32. Fletcher EV et al (2013) EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Mol Cancer Res 11(12):1574-1584. doi: 10.1158/1541-7786.MCR-13-0187
33. Giles KM et al (2013) Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 12(11):2541-2558. doi: 10.1158/1535-7163.MCT-13-0170
34. Stone RL et al (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610-618
35. Narsale AA, Carson JA (2014) Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care 8(4):321-327. doi: 10.1097/SPC.0000000000000091
36. Yao Z et al (2010) TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 107(35):15535-15540. doi: 10.1073/pnas.1009472107
37. Li L et al (2014) Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 20(10):2714-2726. doi: 10.1158/1078-0432.CCR-13-2613
38. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, Grimm EA (2011) Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res 9(11):1537-1550. doi: 10.1158/1541-7786.MCR-11-0279